Our investors

CellCentric is a biotechnology company focused on the development of first-in-class p300/CBP inhibitor, CCS1477 for multiple specific cancer types.

CellCentric is a privately held, UK company with Morningside Ventures as its majority shareholder. Earlier funding came from Providence Investment Company, Takeda Ventures, UK Innovation Science & Seed Fund, Avlar, NESTA and the University of Cambridge.

CellCentric has also benefited from significant non-dilutive financial awards, including from UKRI/Innovate UK.